Abstract
T-cell dysfunction is a hallmark of B-cell Chronic Lymphocytic Leukemia (CLL), where CLL cells downregulate T-cell responses through regulatory molecules including programmed death ligand-1 (PD-L1) and Interleukin-10 (IL-10). Immune checkpoint blockade (ICB) aims to restore T-cell function by preventing the ligation of inhibitory receptors like PD-1. However, most CLL patients do not respond well to this therapy. Thus, we investigated whether IL-10 suppression could enhance antitumor T-cell activity and responses to ICB. Since CLL IL-10 expression depends on Sp1, we utilized a novel, better tolerated analogue of the Sp1 inhibitor mithramycin (MTM
Document Type
Accepted Manuscript
Publication Date
11-1-2021
Repository Citation
Rivas, J R; Liu, Y; Alhakeem, S S; Eckenrode, J M; Marti, F; Collard, J P; Zhang, Y; Shaaban, K A; Muthusamy, N; Hildebrandt, G C; Chen, L; Thorson, J S; Leggas, M; and Bondada, Subbarao, "Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia." (2021). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 154.
https://uknowledge.uky.edu/microbio_facpub/154
